trimurthi has entered into an agreement with GMBU e.V., Halle (Saale), Germany, to facilitate the commercial scale-up of Astaxanthin production. This strategic move aims to transition the product from pilot scale to full commercial manufacturing at the company's research facilities in Hyderabad, India. The development is significant as it marks the progression of Novelix Pharmaceuticals Limited's capabilities in producing high-value nutraceutical ingredients.

The agreement was executed on June 2, 2026, under Regulation 30 of the listing regulations. Disclosures confirm that no special rights, such as the right to appoint directors or preferential share subscription, have been agreed upon between the parties. Furthermore, the transaction does not involve any shareholding in the counterparty entity and is not classified as a related party transaction.

The filing confirms that GMBU e.V. is not related to the promoter or promoter group of Novelix Pharmaceuticals Limited. The agreement was disclosed in compliance with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026. The company's registered office is located at H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Himayat Nagar, Hyderabad, Telangana- 500029.

Key Agreement Details

Promoters of Novelix Pharmaceuticals Limited increased their stake by acquiring 950,000 equity shares through the conversion of warrants on May 29, 2026. The acquisition, executed via a preferential allotment, significantly alters the company's shareholding pattern and strengthens promoter control. Srinidhi Fine Chemicals LLP accounted for the largest portion of this increase, acquiring 800,000 shares, while Narahari Belide acquired 150,000 shares.

The disclosures were submitted to BSE Limited on June 01, 2026, and June 02, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filings detailed the transactions involving promoters and members of the promoter group.

Shareholding Details

The acquisition involved the conversion of warrants held by various promoter group entities. Prior to the acquisition, the company's equity share capital stood at ₹210,850,000, comprising 21,085,000 equity shares of ₹10 each. Following the allotment, the equity share capital increased to ₹238,950,000, comprising 23,895,000 equity shares of ₹10 each.

The following table outlines the changes in shareholding for the key acquirers disclosed: